Achillion Pharmaceuticals
ACHN
ACHN was delisted on the 27th of January, 2020.
147 hedge funds and large institutions have $853M invested in Achillion Pharmaceuticals in 2016 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 55 increasing their positions, 44 reducing their positions, and 20 closing their positions.
178% more call options, than puts
Call options by funds: $10M | Put options by funds: $3.6M
25% more repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 44
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
2% less capital invested
Capital invested by funds: $866M → $853M (-$13M)
2.11% less ownership
Funds ownership: 82.09% → 79.99% (-2.1%)
4% less funds holding
Funds holding: 153 → 147 (-6)
15% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 20
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$11.9M |
| 2 |
Norges Bank
Oslo,
Norway
|
+$6.26M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$4.34M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.91M |
| 5 |
O
OrbiMed
New York
|
+$1.39M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
-$9.15M |
| 2 |
State Street
Boston,
Massachusetts
|
-$6.17M |
| 3 |
Millennium Management
New York
|
-$5.73M |
| 4 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$4.7M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$3.59M |
ACHN Hedge Fund Activity: Q2 2016 in Review
147 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in Achillion Pharmaceuticals (ACHN) for Q2 2016, worth a combined $853M — down 1.5% from $866M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of ACHN and 17 opened new positions — a net loss of 3 holders — while 44 trimmed existing stakes and 55 added.
The largest buyer was Goldman Sachs, adding an estimated $11.9M. The largest seller was Janus Henderson Investors US, cutting an estimated $9.15M.
- 147 institutional investors held Achillion Pharmaceuticals (ACHN) as of Q2 2016, down from 153 in Q1 2016.
- Funds reported $853M of Achillion Pharmaceuticals stock for Q2 2016, down 1.5% quarter-over-quarter.
- 17 funds opened new Achillion Pharmaceuticals positions in Q2 2016 and 20 closed out, a net change of -3 holders.
- The largest Achillion Pharmaceuticals buyer in Q2 2016 was Goldman Sachs, an estimated $11.9M added.
- The largest Achillion Pharmaceuticals seller in Q2 2016 was Janus Henderson Investors US, an estimated $9.15M sold.
Based on aggregated 13F filings for Q2 2016.